Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present American BriVision (Holding) Corporation (OTC: ABVC).

Full DD Report for ABVC

Recent News from (OTC: ABVC)

American Brivision (Holding) Corp. Announces Stock Split of Its Issued and Outstanding Shares of Common Stock at a Ratio of 1-For-3.141
GOSHEN, NY / ACCESSWIRE / April 8, 2016 / American BriVision (Holding) Corp. (OTCQB: ABVC) (the "Company"), a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs, today said that on April 8, 2016 8:00 am Eastern Standard...
Source: ACCESSWIRE IA
Date: April, 08 2016 08:23
MeTu Brands - A $1.6 Billion Penny Stock
In the world of penny stocks, strange things happen. Like Metu Brands ( OTCQB:MTOO ), the $1.6 billion dollar penny stock. With an average trading volume of nearly 0, its extreme illiquidity has caused the few shares available to trade at absurd valuations. It has a few thousand in assets, and...
Source: SeekingAlpha
Date: January, 05 2016 13:16

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-04-19N/A2.00N/AN/A0
2018-04-18N/A2.00N/AN/A0
2018-04-17N/A2.00N/AN/A0
2018-04-16N/A2.00N/AN/A0
2018-04-15N/A2.00N/AN/A0

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-01-161515100.0000Short
2017-03-17100100100.0000Short
2017-03-14100100100.0000Short
2017-03-13100100100.0000Short
2017-03-10100100100.0000Short

* Short Mode

Short Analysis provided by Squeeze Report.


About American BriVision (Holding) Corporation (OTC: ABVC)

Logo for American BriVision (Holding) Corporation (OTC: ABVC)

Currently, we are a holding company operating through our wholly owned subsidiary, American BriVision Corporation, a Delaware corporation BriVision . BriVision was incorporated in in the State of Delaware. It is a biotechnology company focused on the development of new drugs and innovative medical devices to fulfill unmet medical needs. Following the Share Exchange as described herein below , we have abandoned our prior business plan and we are now pursuing BriVision historical businesses and proposed businesses, which focus on the development of new drugs and innovative medical devices to fulfill unmet medical needs. The business model of the Company to integrate research achievements from world famous institutions, conduct clinical trials of translational medicine for Proof of Concept POC , out license to international pharmaceutical companies, and exploit global markets.

 

Contact Information

 

 

Current Management

  • Howard Doong / CEO, President
  • Chun Mu Hung / CFO, Secretary, Treasurer
  • ChiHsin Richard Kin / Chief Scientific Officer
  • Huan Lou / Securities Counsel
  • Jay M. Kaplowitz / Securities Counsel
  • Eugene Jiang / Chairman

Current Share Structure

  • Market Cap: $427,493,294 - 03/19/2018
  • Authorized: 360,000,000 - 03/01/2018
  • Issue and Outstanding: 213,746,647 - 03/01/2018
  • Float: 62,947,381 - 02/14/2017

 


Recent Filings from (OTC: ABVC)

Annual transition reports filed under rule 13a-10 or 15d-10 of the Securities Exchange Act
Filing Type: 10-KTFiling Source: edgar
Filing Date: April, 13 2018
Notification that form 10-K will be submitted late
Filing Type: NT 10-KFiling Source: edgar
Filing Date: April, 03 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 19 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 19 2018
Amendment to a previously filed 10-Q
Filing Type: 10-Q/AFiling Source: edgar
Filing Date: March, 19 2018
OTCQB Certification - OTCQB Certification
Filing Type: OTCQB Certification - OTCQB CertificationFiling Source: OTC Markets
Filing Date: March, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 12 2018
Annual Report - Annual Report
Filing Type: Annual Report - Annual ReportFiling Source: OTC Markets
Filing Date: February, 21 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 14 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: February, 05 2018

 

 


Daily Technical Chart for (OTC: ABVC)

Daily Technical Chart for (OTC: ABVC)


Stay tuned for daily updates and more on (OTC: ABVC)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: ABVC)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

The Subway Trader
@TheSubwayTrader

 

 


Disclaimer: The Subway Trader publishes reports providing information on selected companies. The Subway Trader is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. The Subway Trader accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ABVC is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. The Subway Trader has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. The Subway Trader does not own any shares of ABVC and does not buy, sell, or trade any shares of ABVC. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2016 by The Subway Trader. All rights reserved. Our Full Disclaimer: http://thesubwaytrader.com/disclaimer/

 

 

Release this Report to Investors

Via Email

Via Text

Important

If you would like to schedule the release please Contact Us and we will assist you otherwise we will release this report to investors 15 minutes after payment is received to allow the most current information to be updated before the report is sent. Interested in reaching more investors? Contact Us